¿¹°©Ò©ÎïÃô¸ÐÐÔÊÔÑé,Anticancer drug sensitivity testÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
S180ϸ°û,S180 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈËÔ´»¯µ¥¿Ë¡¿¹Ìå,humanized monoclonal antibodyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÄÔ¼¹Òº¼ì²é,Examination of cerebrospinal fluidÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½þÈóºÍ×ªÒÆ,invasion and metastasisÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºÏÀíÖÎÁÆ,reasonable treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
15-ôÇ»ùǰÁÐÏÙËØÍÑÇâø,15-hydroxyprostaglandin dehydrogenase (15-PGDH)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈÍ´øÑùÁö,Desmoid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ÀÁ¢×¼Ö±Æ÷,asymmetric jawsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹ÑºËÜÕËá΢ÕóÁÐ,oligonucleotide microarrayÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹Ö×Áö¼Á(ÖÐÒ©)/ÖÎÁÆÓ¦ÓÃ,Antineoplastic agents(TCD)/therapeutic useÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Áª¼ì,combined detectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×Áöϸ°ûÒßÃç,Tumor cell vaccineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶à²ãǰÏòÍøÂç,multilayer feedforward neural networksÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ªÒÆÄ£Ê½,transfer modeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¹¦ÂʺÄÉ¢,Power dissipationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
HSV1-TK»ùÒò,HSV1-TK geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´©Í¸Òò×Ó,penetration factorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¼ÊõÖ¸ÄÏ,Technical GuideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÒÖÖÆµ°°×p53,Tumor suppressor protein p53Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈȼÁÁ¿,Thermal doseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÉÏÆ¤-¼äÖÊת»¯,epithelial-mesenchymal transitionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
½ÚÅÄ»¯ÁÆ,metronomic chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
îâ-Ñõ´ØºÏÎï,molybdenum-oxygen clusterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
΢Á¿ÔªËØÎø,Microelement SeleniumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ò©ÎïÊäËÍϵͳ,drug delivery systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼Æ»®ÏµÍ³,planning systemÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»·¾³Ö°©Îï,environmental carcinogensÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿µ°¬×¢ÉäÒº,Kangai injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÍíÆÚÍç¹ÌÐÔ°©Í´,Advanced refractory cancer painÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÊÊÐε÷Ç¿·ÅÁÆ,IMRTÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸ß¾Û½ðÆÏËØ,Highly Agglutinative StaphylococcinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ªÒÆÐÔÖ×Áö,Metastatic tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×÷Óðеã,effect targetÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÈýάÂ˲¨Æ÷,3-dimentional filterÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûˮƽ,Cellular levelÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ô´úÖ×Áöϸ°û,primary cancer cellsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ºËÌÇÌåµ°°×L11,ribosome protein L11Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸öÌ廯ҽÁÆ,Personalized medicineÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸¹Ç»Éñ¾´Ô,Celiac plexusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
B³¬Í¼Ïñ,B-mode ultrasound imageÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÀÏÄêÖ×Áö»¼Õß,Aged Cancer PatientsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×ªÒÆÏà¹Ø»ùÒò1,metastasis-associated gene 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
O~6-¼×»ùÄñàÑßÊ-DNA¼×»ù×ªÒÆÃ¸,O~6-methylguanine-DNA methyltransferaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿¹ÁöÉý°×Ƭ,Kangliu Shengbai tabletÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
×¢Á¿Í¼,fluence mapÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¸´·½°¢½º½¬,compound E Jiao JiangÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éý°×,leukogenic actionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ó¼ÁÁ¿¼×°±µûßÊ,high-dose methotrexateÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
θÃÚËØÊÍ·ÅëÄ,Gastrin-releasing peptideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ×éÈËP53ÏÙ²¡¶¾,recombinant human ad-p53 injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏËÈÜøԼ¤»îÒÖÖÆÎï1,plasminogen activator inhibitor 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ãæ²¿ÒÆÎ»Èë·,Transmaxillary approachÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Êý×ÖÖØ½¨Ó°Ïñ,digitally reconstructed radiographsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·ÅÆúÖÎÁÆ,abandoning treatmentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
÷¾×µ,sacrumÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ó»ÆËØÑÜÉúÎï,emodin derivativeÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ¸´°©,multiple primary malignant tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÀäÑ»·Î¢²¨µ¶,transcatheter arterial chemoembolizationÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éϸ¹ÏÂÉñ¾´Ô,Superior Hypogastric plexusÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ͼÏñÈںϼ¼Êõ,Image Fusion TechniqueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
»ùÒò¶àëÄÐÔ,Gene polymorphismÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ñ»µ¨×ÓÓÍÈé,Brucea javanica oil emulsionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
±´Àà¶àÌÇ,Shellfish polysaccharideÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Äæ×ªÄÍÒ©,Reversal of multidrug-resistanceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ƽºâ·¨ÐÄѪ³ØÏÔÏñ,Gated blood pool imagingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖØ×éÈ˰×ϸ°û½éËØ-2,RhIL-2Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Cks1µ°°×,Cyclin kinase subunit 1Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ôÇ¿¼Íª¿ØÊÍÆ¬,Controlled-release oxycodoneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°ûÖÜÆÚµ°°×ÒÀÀµÐÔ¼¤Ã¸ÒÖÖÆ¼Á,Cyclin-dependent kinase inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©Í´ÖÎÁÆ,cancer pain managementÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
δ֪Է¢Ôî,unknown primaryÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
patched»ùÒò,patched geneÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ñ£ºÛ°©,Scar cancerÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ì岿¶ñÐÔÖ×Áö,Bodily malignant neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
°©Ï¸°ûÖê,cancer cell strainÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µ¥´¿ðåÕ¶¾ÐØÜÕ¼¤Ã¸,Herpes simplex virus thymidine kinaseÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´ÅÐÔ±ê¼Ç,Magnetic labelingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÒÁÎÄ˼À¼,Evans blueÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¦ÁV¦Â3ÕûºÏËØ,¦ÁV¦Â3 integrinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÖÃÈëÊõ,stents interventingÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÁªºÏ·ÅÁÆ,combination radiotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÏËάÐÔÖ×Áö,fibrous tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÜñÂóÒȵ°°×øÒÖÖÆ¼Á,buckwheat trypsin inhibitorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
µç×ÓÉäÒ°Ó°Ïñ×°ÖÃ,electronic portal imaging device (EPID)Ó¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¼¤¹âÓÕµ¼×ÔÌåÓ«¹â,laser induced autofluorescenceÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶ñÐÔʵÌåÖ×Áö,malignant solid tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
·Ö×Ó°ÐÏòÒ©Îï,Molecular Targeting DrugÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ÐÓ»¨Óê×¢ÉäÒº,xinghuayu injectionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èí×éÖ¯ÏÙÅÝ×´,alveolar soft partÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
СԲϸ°ûÖ×Áö,small round cell tumorsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Éî¶È¼ÁÁ¿·Ö²¼,depth-dose distributionÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¿ÚÇ»¼ÙË¿½Íĸ¾ú,oral CandidaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Èȹà×¢»¯ÁÆ,hyperthermal perfusion chemotherapyÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
È˸ΰ©Bel-7402ϸ°û,Human hepatocellular carcinoma Bel-7402 cellÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Numbµ°°×,Numb proteinÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
Ö×ÁöÏà¹ØÐÔÆ¶Ñª,cancer-related anemiaÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
ϸ°û±£»¤¼Á,pretective agentÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
´Ù½áµÞ×éÖ¯ÔöÉúÐÔСԲϸ°ûÖ×Áö,desmoplastic small round cell tumorÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«
¶àÔ·¢¶ñÐÔÖ×Áö,Multiple primary malignant neoplasmsÓ¢Óï¶Ì¾ä,Àý¾ä´óÈ«

|